ASHM Report Back
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
Day One review GLASGOW 2016
Hello from Glasgow. What an amazing first day we have had.
The program today was a great mix of new information and case studies.
I was surprised to start the day with a Hepatitis C session but it was really informative.
Take Home message from this session - in the context of HIV positive individuals, it may take 12 months for the HCV antibody yest to become positive - hence if suspicious , do HCV PCR.
Ian Mc Gowan from the University of Pittsburgh discussed long acting ARVs for both treatment and prevention which will be a great advancement for those patients with adherence problems - drug and alcohol usage and mental health issues.
Currently phase 2 studies for Rilpivirine and Cabotegravir - an analogue of Dolutegravir - a booster dose initially and then dosing every 4-8 weeks.
Also EFdA which is a long acting formulation which would last 12 months - an implanon like device.
The highlight of the day for me was Dr Anthony Fauci from the National Institute of Allergy and Infectious Diseases who delivered the Joep Lange and Jacqueline van Tongeren Memorial Lecture.
He spoke of Ending the HIV/AIDS pandemic by following the science. He spoke of the advances since the first HIV notifications in 1981 and how far we had come. South Africa are about to enter into a phase 2 trial with a vaccine!! it was incredible to reflect on how far we have come in the last 35 years but looking at the incidence around the world, how for we still have to go.
Is 90,90,90 really achievable? Some of the audience felt that it would never be achievable in their country but ....... did we ever envisage the possibility of a vaccine? We live in hope.
Andrew Hill from St Stephens AIDS Trust at the Chelsea and Westminster Hospital spoke the the difference in cost of drugs in different countries - a really contentious issue. We do not know how lucky we re in Australia to be able to treat as many patients as we want for HCV.
Looking forward to Day 2. Thank you ASHM for this amazing opportunity!